BioRegenx, Inc. (OTC: BRGX) Celebrates Key Developments
BioRegenx, Inc. (“BioRegenx” or the “Company”) (OTC: BRGX), based in Chattanooga, is at the forefront of health technology, focusing on non-invasive diagnostic solutions that advance microvascular and metabolic health. Recently, the Company reached several impactful milestones that symbolize its commitment to innovation.
Significant Corporate Progress
As part of its ongoing growth, BioRegenx has engaged a new PCAOB-registered independent auditor. This decision follows extensive SEC actions impacting many audit firms. By choosing a new auditor, the Company reaffirms its commitment to transparency and precise financial reporting.
The Company is also receiving support from Sichenzia Ross Ference Carmel LLP, a law firm from New York. With their guidance, BioRegenx is effectively navigating its corporate uplisting strategy and expanding its capital market connections. This collaboration is playing a vital role in shaping the Company's governance framework.
Innovative Technology and Developments
Following their acquisition of DocSun Biomedical Holdings, Inc. last year, BioRegenx has integrated advanced non-contact vital-sign detection technology into its offerings. This innovative system utilizes AI tools and optical sensors to measure vital signs like heart rate and oxygen saturation, eliminating the need for any physical contact.
The newly-formed partnership with DocSun has allowed for exploration of joint ventures with various recognized technology firms. Several non-binding Letters of Intent (LOIs) are in place to discuss potential Software Development Kit (SDK) integrations. This reflects a strong industry interest in DocSun’s advanced capabilities and positions BioRegenx at the intersection of health tech and AI.
GlycoCheck®: A Cornerstone for Vascular Health
A critical component of BioRegenx's innovation strategy is the GlycoCheck® system. Through a partnership with Microvascular Health Solutions (MVHS) and academic institutions, BioRegenx has secured a global distribution license for this clinically validated vascular diagnostic platform.
The GlycoCheck® technology boasts a strong scientific foundation, supported by numerous peer-reviewed studies that confirm its effectiveness in assessing microvascular health. This system has been implemented globally across educational institutions, research facilities, and healthcare clinics, generating substantial revenue. Ongoing developments aim to merge GlycoCheck® with AI technologies for a comprehensive approach to detecting cardiovascular risks and optimizing health.
Strategic Vision for the Future
BioRegenx's strategic vision aligns AI analytics with the GlycoCheck® platform. The goal is to enhance predictive insights into vascular and metabolic health, granting healthcare providers the ability to identify conditions early and effectively.
CEO Bill Resides emphasized this vision, stating that the integration of DocSun’s intelligence with the GlycoCheck® platform is paving the way for a healthier future, where monitoring vascular health becomes a continuous, non-invasive process.
Corporate Commitment to Health Technology
As BioRegenx advances its portfolio, the Company remains dedicated to research and development that abide by regulatory standards. The future of non-invasive vascular assessments looks promising, with the market for such technologies expected to exceed $20 billion annually. BioRegenx aims to harness this commercial potential while maintaining a focus on responsible technology commercialization.
Frequently Asked Questions
What is BioRegenx, Inc. (OTC: BRGX)?
BioRegenx is a health technology company focused on innovative non-invasive diagnostics and predictive analytics for enhancing microvascular and metabolic health.
What recent milestones has BioRegenx achieved?
Recent milestones include engaging a new independent auditor and integrating DocSun’s AI technology into their health analytics strategy.
How does GlycoCheck® contribute to health diagnostics?
GlycoCheck® provides clinical insights into microvascular health, correlating with various health conditions, which supports its commercial and research applications.
What role does AI play in BioRegenx's strategy?
AI is pivotal in enhancing data analytics for health assessments, enabling more accurate and predictive insights into health conditions through integration with existing technologies.
Where can I find more information about BioRegenx?
More information can be found on BioRegenx’s official website, where they provide updates on their technology, developments, and investor relations.
